Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
31.23
-0.53 (-1.67%)
At close: Aug 1, 2025, 4:00 PM
31.24
+0.01 (0.03%)
After-hours: Aug 1, 2025, 7:50 PM EDT

Company Description

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.

The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.

In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop.

The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023.

Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Harrow, Inc.
Harrow logo
CountryUnited States
Founded1998
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees382
CEOMark Baum

Contact Details

Address:
1A Burton Hills Boulevard, Suite 200
Nashville, Tennessee 37215
United States
Phone615 733 4730
Websiteharrow.com

Stock Details

Ticker SymbolHROW
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001360214
CUSIP Number415858109
ISIN NumberUS4158581094
Employer ID45-0567010
SIC Code2834

Key Executives

NamePosition
John P. Saharek MBAPresident and Chief Executive Officer of Harrow's ImprimisRx Division
Mark L. Baum J.D.Chief Executive Officer and Chairman of the Board
Andrew R. Boll C.F.A., C.M.A.Chief Financial Officer and Corporate Secretary
Dr. Amir H. Shojaei Ph.D., Pharm.D.Chief Scientific Officer
Jamie WebbDirector of Communications and Investor Relations
Brett A. BurrellVice President of Legal and Compliance
Kim BarrattChief Talent Officer
Dr. Mark A. Mannebach Ph.D., R.Ph.Head of Regulatory Affairs and Pharmacovigilance
Greg DiPasqualeSenior Vice President and Head of Commercial

Latest SEC Filings

DateTypeTitle
Jul 17, 20258-KCurrent Report
Jun 20, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 20, 20258-KCurrent Report
Jun 9, 20258-KCurrent Report
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Apr 25, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025DEF 14AOther definitive proxy statements
Apr 7, 2025SCHEDULE 13D/AFiling
Mar 27, 202510-KAnnual Report